Seeking Alpha

Pannobhaso's  Instablog

Pannobhaso
Send Message
A researcher into gene silencing as a technology for improving the lives of those suffering from incurable diseases. Benitec Biopharma is my primary investment in this technology as ddRNAi offers one-time treatments for a broad range of these diseases.
  • What Goes Around, Comes Around 3 comments
    May 14, 2014 12:11 PM | about stocks: BNIKF

    Ten years ago, almost to the day, Benitec (OTCPK:BNIKF) from (then) Queensland, Australia acquired a small US company called Avocel, based in Sunnyvale California. Benitec's management at the time thought the acquisition would give them access to the first ddRNAi therapy that would be ready for clinical trial. So confident were they that they announced that this ddRNAi treatment for Hepatitis C (HCV) would be in clinical trial in 2005.

    With this investment also came a laboratory and a number of clever scientists, including Dr Mark Kay of Stanford University.

    A year later, in May 2005, Benitec announced that it had "identified a highly promising clinical candidate for its RNA interference (RNAi)-based therapeutic against the hepatitis C virus (HCV)". The company said that it was on track to start a Phase 1 trial in the later half of 2006.

    Almost a year after that announcement, in April 2006, Benitec announced that it was reducing its presence in the US by cutting back 50% of its staff in order to preserve capital. It was acknowledged at the time that the cut-backs would slow the rate of progress on the HCV treatment. A month later, while running out of capital, Benitec closed its US operation.

    As part of the closure arrangements, the US operation of Benitec morphed into Tacere, which became a ddRNAi licensee, and it was this company which carried on with the development of what became TT-033.

    Benitec was, at that time, involved with the City of Hope in the development of a cure for HIV. This became its primary focus and the resulted in the first clinical trial of ddRNAi.

    In 2008 Pfizer (NYSE:PFE) saw an opportunity and announced a partnership with Tacere for the development of TT-033. Through cooperation and after rigorous testing, the two companies realised that, at therapeutic levels, TT-033 was going to induce toxicity. TT-033 was thus refined over the "Pfizer years" and became TT-034.

    Unfortunately, just when TT-034 looked destined to make it to the clinic, Pfizer decided to close down all its RANi research programs.

    After being in the wilderness for twelve months or so, Tacere was re-acquired by Benitec for what could prove to be be bargain of the century.

    Now, ten years on, and with cash in its coffers Benitec is re-establishing its laboratory in California. The Lab will be headed by Dr Suhy who is the lead scientist for the development of TT-034. Dr Suhy will be joined by other members of the old Tacere team who, with a lab and cash in hand, will be able to further the company's research into its other pipeline products for ailments such as Age Related Macular Degeneration.

    The lab represents the future of Benitec. Through its work, new patents for new treatments will be developed. But first TT-034, which is likely to be administered to the first patient before the end of this May, will be rolled into a clinical setting almost exactly ten years after the story started. What goes around, comes around.

    Themes: Pfizer, Benitec, ddRNAi, RNAi, HCV Stocks: BNIKF
Back To Pannobhaso's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (3)
Track new comments
  • brama66
    , contributor
    Comments (107) | Send Message
     
    Great historical reflection, Panno. Gives new and even some long investors a peek behind the time-travel curtain on what really could be the "deal of the century". With TT-034 results, and current blogs, results, on the Calimmune trial, things could look seriously ripe for Benitec by the end of this year. Especially if that Calimmune Job posting in Australia is a sign of an upcoming trial. Sit back and eat popcorn my friends, cuz the next 12 months is going to really get interesting.
    14 May, 07:25 PM Reply Like
  • SmokeyNYY
    , contributor
    Comments (85) | Send Message
     
    Thanks for the article.
    15 May, 01:19 AM Reply Like
  • danno123
    , contributor
    Comments (2) | Send Message
     
    excellent information Panno reminds me why I have been with it for so long -- this little company is going to change the world as we now know it - for everyone to benefit .. Benefit from Benitec .- got a nice ring to it .. this is going to "FLY" .. Im so glad to be a small part of it .. something to be proud of and tell my grandchildren.
    Dan
    16 May, 07:26 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Most Commented
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.